馃嚙馃嚪路3d agoRegulatory
Medicamentos oncol贸gicos considerados essenciais pela OMS ainda n茫o chegam aos pacientes do SUS, aponta levantamento da Interfarma
Publisher
I
Interfarma Brazil
Brazil
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Interfarma Brazil
- Region
- Brazil
- Scope
- Regulatory
- Published
- July 24, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on interfarma.org.br
Leave the platform to read the original full article on the publisher site.
Source: Interfarma Brazil
Scope: Regulatory
Related coverage
More related coverage
FDA Drug Safety Communications/5h ago
American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter
MHRA UK/5h ago
Guidance: AI Airlock Sandbox Phase 2 Programme Report
UK Department of Health and Social Care/7h ago
Medicine supply disruption statistics, UK: data to June 2026
Twice-yearly official statistics on medicine supply issue and discontinuation notifications reported...
Interfarma Brazil/7h ago